As a result, inhibition of the TGF‐β pathway is currently considered as a potential therapeutic option in advanced cancers, and encouragingly, several anti‐TGF‐β agents in clinical trials have shown promising results 1, 2. The gene discussed is TGFB1; the disease is cancer.